PARP1 and acute kidney injury: Most studies, including the ischemic AKI model, either treated animals with PARP inhibitors before or immediately after tissue injury or used a genetically PARP ablation model; therefore, the effects of PARP inhibitors on the healing phase after tissue injury remain unknown11–15.